< Back to previous page
Patent
Mucin isoforms in diseases characterized by barrier dysfunction
The present invention relates to the field of mucin isoforms, more in particular for use in the diagnosis, monitoring, prevention and/or treatment of a disease characterized by barrier dysfunction, such as but not limited to a gastrointestinal disorder (e.g. Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), cancer, gastro-intestinal infections, obesitas, non-alcoholic fatty liver disease (NAFLD)), neurodegenerative disorders, respiratory infections,... In a specific embodiment, said mucin isoform is selected from the list comprising: MUC1 isoforms and MUC13 isoforms.
Patent Publication Number: WO2021013479
Year filing: 2021
Year approval: 2022
Year publication: 2021
Status: Requested
URI: link to Espacenet
Technology domains: Analysis of biological materials, Pharmaceuticals
Validated for IOF-key: Yes
Attributed to: Associatie Universiteit & Hogescholen Antwerpen